SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973–1999. Bethesda: National Cancer Institute, 2000. Available from URL: http://seer.cancer.gov/csr/1973_1999/[accessed March 3, 2003].
  • 2
    Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001; 19: 379382.
  • 3
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80: 15881594.
  • 4
    Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19: 558567.
  • 5
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335: 17851791.
  • 6
    Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88: 10821090.
  • 7
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996; 334: 488493.
  • 8
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377387.
  • 9
    Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial. J Clin Oncol. In press.
  • 10
    Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982; 10: 11001120.
  • 11
    Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23: 129138.
  • 12
    Clark JI, Gaynor ER, Martone B, et al. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-α in patients with advanced renal cell carcinoma. Clin Cancer Res. 1999; 5: 23742380.
  • 13
    Kankuri M, Pelliniemi TT, Pyrhonen S, Nikkanen V, Helenius H, Salminen E. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a Phase II study. Cancer. 2001; 92: 761767.
  • 14
    Godley P, Kim SW. Renal cell carcinoma. Curr Opin Oncol. 2002; 14: 280285.
  • 15
    Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 16551659.
  • 16
    Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358: 966970.
  • 17
    Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002; 29(Suppl 7): 4146.
  • 18
    Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Safety. 1999; 21: 389406.